Inclusion Criteria:  Gastric adenocarcinoma diagnosed by histology. Ambulatory cases, 18-75 years old ECOG performance status ≤ 1 Have not received anti-tumor therapy previously (such as surgery, radiotherapy, chemotherapy, targeted therapy, immunotherapy) Patients able to tolerate abdominal surgery above grade 3  Has adequate organ function as defined by the following criteria:  WBC> 4.0×10^9/L ANC> 1.5×10^9/L ANC ≥ 1.5×10^9/L HB ≥ 80 g/L PLT ≥ 100×10^9/L TBIL ≤ 1.5×ULN ALT and AST <2.5 × ULN, for patients with liver metastases, ALT and AST <5 × ULN BUN and Cr ≤ 1.5 × ULN or endogenous creatinine clearance ≥ 50 mL/min No history of other tumors Be willing and able to comply with the plan during the research period Has given written informed consent Life expectancy ≥ 6 months  Exclusion Criteria:  Those with a history of other malignancies in the last 5 years, except for cured non-melanoma skin cancer and cervical carcinoma in situ HER-2+ and willing to receive Trastuzumab Pregnancy or breast-feeding women; Men and women who are sexually active (possible to have children) and unwilling to use contraception during the study period Severe, uncontrolled medical diseases and infections; chronic bowel disease or short bowel syndrome Major organ failure, such as compensatory cardiopulmonary liver and kidney failure; severe liver and kidney metabolism abnormalities, affecting the normal metabolism of drugs Patients with other surgical contraindications, such as serious diseases that are difficult to control The researcher believes that patients with a clear gastrointestinal bleeding tendency and/or patients with abnormal blood coagulation function (INR > 1.5) Active HBV or HCV Peripheral neuropathy ≥ Grade 2 according to NCT-CTC AE5.0 Patients who are allergic to the drugs in this study, or determined by the investigator as unsuitable to participate in this clinical study